This analysis of 116 isavuconazole therapy courses shows that hepatic test disturbances (HTDs) were relatively frequent (29% of cases) but rarely led to treatment interruption (5%). Importantly, patients with baseline HTDs, including those attributed to a first-line triazole, did not exhibit a higher risk of subsequent HTD under isavuconazole therapy.
Keywords: aspergillosis; hepatotoxicity; liver; mucormycosis; triazoles.
© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.